Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 587401, 4 pages
http://dx.doi.org/10.1155/2008/587401
Review Article

Do PPAR 𝛾 Ligands Suppress the Growth of Cholangiocarcinoma or the Cholangiohepatitis Induced by the Tumor?

Department of Aging Medicine and Geriatrics, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan

Received 5 February 2008; Accepted 9 June 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Satoru Suzuki and Kiyoshi Hashizume. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Mudaliar and R. R. Henry, “New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers,” Annual Review of Medicine, vol. 52, pp. 239–257, 2001. View at Publisher · View at Google Scholar
  2. S. Suzuki, J. Mori, M. Yamazaki, A. Sato, W. Hosoda, and K. Hashizume, “Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma,” Internal Medicine, vol. 46, no. 20, pp. 1723–1728, 2007. View at Publisher · View at Google Scholar
  3. C. Han, A. J. Demetris, G. K. Michalopoulos, Q. Zhan, J. H. Shelhamer, and T. Wu, “PPARγ ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21WAF1/Cip1 pathway,” Hepatology, vol. 38, no. 1, pp. 167–177, 2003. View at Publisher · View at Google Scholar
  4. H. Okano, K. Shiraki, H. Inoue et al., “The PPARgamma ligand, 15-deoxy-delta 12,14-PGJ2, regulates apoptosis-related protein expression in cholangio cell carcinoma cells,” International Journal of Molecular Medicine, vol. 12, no. 6, pp. 867–870, 2003. View at Google Scholar
  5. T. Kobuke, S. Tazuma, H. Hyogo, and K. Chayama, “A ligand for peroxisome proliferator-activated receptor γ inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma,” Digestive Diseases and Sciences, vol. 51, no. 9, pp. 1650–1657, 2006. View at Publisher · View at Google Scholar
  6. C. Han, A. J. Demetrist, Y. Liu, J. H. Shelhamer, and T. Wu, “Transforming growth factor-β (TGF-β) activates cytosolic phospholipase A2α (cPLA2α)-mediated prostaglandin E2(PGE)2/EP1 and peroxisome proliferator-activated receptor-γ (PPAR-γ)/Smad signaling pathways in human liver cancer cells: a novel mechanism for subversion of TGF-β-induced mitoinhibition,” The Journal of Biological Chemistry, vol. 279, no. 43, pp. 44344–44354, 2004. View at Publisher · View at Google Scholar
  7. Y. Shimizu, A. J. Demetris, S. M. Gollin et al., “Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells,” International Journal of Cancer, vol. 52, no. 2, pp. 252–260, 1992. View at Publisher · View at Google Scholar
  8. D. Auboeuf, J. Rieusset, L. Fajas et al., “Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997. View at Publisher · View at Google Scholar
  9. T. P. Combs, J. A. Wagner, J. Berger et al., “Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR? agonists: a potential mechanism of insulin sensitization,” Endocrinology, vol. 143, no. 3, pp. 998–1007, 2002. View at Publisher · View at Google Scholar
  10. B. M. Spiegelman, “PPAR-γ: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998. View at Publisher · View at Google Scholar
  11. P. Arner, “The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones,” Trends in Endocrinology and Metabolism, vol. 14, no. 3, pp. 137–145, 2003. View at Publisher · View at Google Scholar
  12. P. Utaisincharoen, S. Ubol, N. Tangthawornchaikul, P. Chaisuriya, and S. Sirisinha, “Binding of tumour necrosis factor-alpha (TNF-α) to TNF-RI induces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines,” Clinical & Experimental Immunology, vol. 116, no. 1, pp. 41–47, 1999. View at Publisher · View at Google Scholar
  13. U. C. Nzeako, M. E. Guicciardi, J.-H. Yoon, S. F. Bronk, and G. J. Gores, “COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells,” Hepatology, vol. 35, no. 3, pp. 552–559, 2002. View at Publisher · View at Google Scholar
  14. S. Ohira, M. Sasaki, K. Harada et al., “Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-a and stromal-derived factor-1 released in stroma,” The American Journal of Pathology, vol. 168, no. 4, pp. 1155–1168, 2006. View at Publisher · View at Google Scholar
  15. N. Ishimura, H. Isomoto, S. F. Bronk, and G. J. Gores, “Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells,” American Journal of Physiology, vol. 290, no. 1, pp. G129–G136, 2006. View at Publisher · View at Google Scholar
  16. Y. Tanimura, T. Kokuryo, N. Tsunoda et al., “Tumor necrosis factor a promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2,” Cancer Letters, vol. 219, no. 2, pp. 205–213, 2005. View at Publisher · View at Google Scholar
  17. T. Yamauchi, J. Kamon, H. Waki et al., “The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity,” Nature Medicine, vol. 7, no. 8, pp. 941–946, 2001. View at Publisher · View at Google Scholar
  18. W.-S. Yang, C.-Y. Jeng, T.-J. Wu et al., “Synthetic peroxisome proliferator-activated receptor-? agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients,” Diabetes Care, vol. 25, no. 2, pp. 376–380, 2002. View at Publisher · View at Google Scholar
  19. D. P. Rose, S. M. Haffner, and J. Baillargeon, “Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women,” Endocrine Reviews, vol. 28, no. 7, pp. 763–777, 2007. View at Publisher · View at Google Scholar
  20. P. De Vos, A.-M. Lefebvre, S. G. Miller et al., “Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor ?,” The Journal of Clinical Investigation, vol. 98, no. 4, pp. 1004–1009, 1996. View at Publisher · View at Google Scholar
  21. L. Vona-Davis and D. P. Rose, “Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression,” Endocrine-Related Cancer, vol. 14, no. 2, pp. 189–206, 2007. View at Publisher · View at Google Scholar
  22. J. M. Way, W. W. Harrington, K. K. Brown et al., “Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor ? activation has coordinate effects on gene expression in multiple insulin-sensitive tissues,” Endocrinology, vol. 142, no. 3, pp. 1269–1277, 2001. View at Publisher · View at Google Scholar
  23. M. Mutoh, N. Niho, and K. Wakabayashi, “Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice,” Biological Chemistry, vol. 387, no. 4, pp. 381–385, 2006. View at Publisher · View at Google Scholar
  24. S. Elchuri, M. Naeemuddin, O. Sharpe, W. H. Robinson, and T.-T. Huang, “Identification of biomarkers associated with the development of hepatocellular carcinoma in CuZn superoxide dismutase deficient mice,” Proteomics, vol. 7, no. 12, pp. 2121–2129, 2007. View at Publisher · View at Google Scholar
  25. G. Wang, Y. Gong, J. Anderson et al., “Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells,” Hepatology, vol. 42, no. 4, pp. 871–879, 2005. View at Publisher · View at Google Scholar
  26. U. A. Boelsterli and M. Bedoucha, “Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: insights from models of obesity and type 2 diabetes,” Biochemical Pharmacology, vol. 63, no. 1, pp. 1–10, 2002. View at Publisher · View at Google Scholar
  27. J. Chilcott, P. Tappenden, M. L. Jones, and J. P. Wight, “A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus,” Clinical Therapeutics, vol. 23, no. 11, pp. 1792–1823, 2001. View at Publisher · View at Google Scholar
  28. K. G. Tolman, V. Fonseca, M. H. Tan, and A. Dalpiaz, “Narrative review: hepatobiliary disease in type 2 diabetes mellitus,” Annals of Internal Medicine, vol. 141, no. 12, pp. 946–956, 2004. View at Google Scholar
  29. L. D. May, J. H. Lefkowitch, M. T. Kram, and D. E. Rubin, “Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy,” Annals of Internal Medicine, vol. 136, no. 6, pp. 449–452, 2002. View at Google Scholar